Keywords: Preclinical Image Analysis, Modelling, Breast, Cancer, Vascular, Image Reconstruction
Motivation: Metronomic chemotherapy shows promise as a cost-effective therapy for vascular normalization. However, it is unclear how to determine the optimal biological dose (OBD).
Goal(s): Our goal is to use dynamic contrast-enhanced (DCE) MRI and pharmacokinetic analysis for non-invasive measurements of the heterogenous tumor treatment response toward determining the OBD.
Approach: The 4T1 murine orthotopic triple negative breast cancer models were assessed longitudinally using two different dosing schemes, daily and intermittent, using cyclophosphamide. Pharmacokinetic and histological analysis (CD31, Ki67) were conducted.
Results: The intermittent dosing schedule showed higher Vp, Fp, and Ktrans in all tumor regions indicating possible vascular normalization.
Impact: The proposed 3D-UTE-GRASP DCE-MRI method provides a non-invasive platform to assess for optimal biological dose in metronomic chemotherapy. By accurately determining the heterogenous tumor vessel dynamical changes, this platform can be used to enhance treatment response over time.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords